NEOADJUVANT TREATMENT IN LOCALLY ADVANCED NON-SMALL CELL LUNG-CANCER

被引：8

作者：

FABER, LP

BONOMI, PD

机构：

[1] Departments of Cardiovascular and Thoracic Surgery, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois

[2] Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois

来源：

SEMINARS IN SURGICAL ONCOLOGY | 1990年 / 6卷 / 05期

关键词：

chemotherapy; preoperative treatment; radiation; stage III non‐small cell lung cancer;

D O I：

10.1002/ssu.2980060506

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Any neoadjuvant or preoperative treatment program that would increase survival in clinically advanced non‐small cell lung cancer (NSCLC) patients would be of significant benefit. In addition to improving patient survival, the program should be associated with minimal toxicity and surgical mortality. The rationale for any preoperative program is that the ability to resect the advanced cancer will be enhanced and micrometastasis will be eradicated. We have analyzed 323 patients enrolled in various types of neoadjuvant and preoperative studies. Review of this data indicates that cisplatin containing regimens produce relatively high responder rates in locally advanced NSCLC patients, resectability rate can be increased by a neoadjuvant program and chemotherapeutic toxicity and operative mortality are not prohibitive. Survival data frequently includes T3NO‐1 patients, but there does appear to be increased survival at 3 and 4 years. These studies remain experimental and continued analysis is necessary before they can be accepted as standard therapy for clinically advanced NSCLC cancer. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company

引用

页码：255 / 262

页数：8

共 27 条

[1] Bromley LL, Szur L, Combined radiotherapy and resection for carcinoma of the bronchus, experience with 66 patients, Lancet, 2, pp. 937-947, (1955)
[2] Bloedorn FG, Rationale and benefit of pre‐operative irradiation in lung cancer, JAMA, 196, pp. 128-129, (1966)
[3] Takita H, Hollinshead AC, Rizzo DJ, Et al., Treatment of inoperable lung carcinoma. A combined modality approach, Ann Thorac Surg, 28, pp. 363-368, (1979)
[4] Mountain CF, A new international staging system for lung cancer, Chest, 89, pp. 225-233, (1986)
[5] Trastek VF, Pairolero PC, Piehler JM, Et al., En bloc (non‐chest wall) resection for bronchogenic carcinoma with parietal fixation, J Thorac Cardiovasc Surg, 87, pp. 352-358, (1984)
[6] Frytak S, Eagan RT, Sawamurak K, Et al., Treatment of limited stage III non‐small cell carcinoma of the lung, Cancer Invest, 6, pp. 193-207, (1988)
[7] Pearson FG, Radical surgery for N<sub>2</sub> disease, Chest, 89, pp. 339-349, (1986)
[8] Martini N, Flehinger BJ, Zaman MB, Et al., Results of resection in non‐oat cell carcinoma of the lung with mediastinal lymph node metastases, Ann Surg, 198, pp. 386-396, (1984)
[9] Naruke T, Goya T, Tsuchiya R, Et al., The importance of surgery to non‐small cell carcinoma of the lung with mediastinal lymph node metastases, Ann Thorac Surg, 46, pp. 603-610, (1988)
[10] Stanley KE, Prognostic factors for survival in patients with inoperable lung cancer, JNCI, 65, pp. 25-32, (1980)

← 1 2 3 →